Hepatitis B virus (HBV) coinfection is a main cause of liver-related mortality in human immunodeficiency virus (HIV)-infected subjects, with an 8-fold increase in mortality risk [1] . Unfortunately, HIV-infected subjects show a low rate of response to standard HBV vaccination (23%-56%), in contrast to rates 190% found in the general population [2] . Among other factors [3],
munization processes. Thus, depletion of T reg cells in mice prior to immunization or infection helped to accomplish infectious pathogen elimination, reduced inflammation, and increased the response to immunization antigens [12] [13] [14] [15] [16] . Additionally, in humans, T reg cells at the margins of lymphoid tissue germinal centers might also act on B cells to inhibit the immunoglobulin class switching necessary for a successful antibody response [15, 16] . All of these observations, together with the fact that T reg cell frequency has been reported to be higher in the peripheral blood of HIV-infected subjects than in healthy donors [17] , directed us to hypothesize that T reg cells could play an important role in the low seroconversion rates reported after HBV vaccination among HIV-infected subjects.
Other cellular parameters, such as distribution of T cellular subsets [5] or their degree of activation [18] , could also be related to the unresponsiveness to HBV vaccine. On the other hand, to our knowledge, no study has focused on the possible influence of recent thymic emigrants (RTEs), although an increase in naive T cells directly exported from the thymus could contribute to improving the response to vaccine antigens by the increase in the TCR repertoire.
Hence, our aim was to analyze the possible involvement of T reg cells and other immunological parameters, such as the frequency of naive cells, memory cells, and RTEs, as well as activation levels, in both CD4 and CD8 T cells, in relation to the unresponsiveness to HBV vaccine in HIV-infected subjects.
PATIENTS AND METHODS

Study participants.
Our study includes HIV-infected subjects from an Assistance Vaccination Program of the Infectious Diseases Service from the Virgen del Rocío University Hospital, Seville, Spain. Inclusion criteria for this program were no previous vaccination against HBV, negative result for HBV serological markers (HBsAg, anti-HBs and anti-HBc), CD4 T cell counts у350 cells/mL, be asymptomatic at the entry in the study, and not receiving cytostatic drugs or immunomodulating therapies (interferons or coreceptor antagonists) that could modify HBV response. Forty HIV-infected subjects from that program with available fresh blood samples at the beginning of the immunization protocol were consecutively recruited from January to July 2008. Written informed consent was obtained from all study participants. The study was approved by the ethics review board from the University Hospital Virgen del Rocío.
Vaccine administration. All patients received 3 intramuscular (deltoid region) double doses (40 mg) of the recombinant Engerix-B vaccine at 0, 1, and 3 months. Before each dose administration and 3 months after the last one (6 months from baseline), the titer of anti-HBs antibody was determined. Patients were defined as nonresponders if they did not achieve an anti-HBs level of у10 mIU/mL. Thus, the patients were considered very early nonresponders, early nonresponders, or final nonresponders if they did not achieve an adequate serological response after the first, the second, or the third dose of HBV vaccine, respectively.
Laboratory measurements. Absolute numbers of CD4 and CD8 T cells were determined with an Epics XL-MCL flowcytometer (Beckman-Coulter). Plasma HIV-1 RNA levels were measured with a quantitative polymerase chain reaction (PCR) (COBAS Ampliprep/COBAS Taqman HIV-1 test, Roche molecular systems), according to the manufacturer's instructions. The detection limit was 1.6 log HIV RNA copies/mL. Plasma samples were tested for HBV-related markers (HBsAg, antiHBs, and anti-HBc) and anti-hepatitis C virus (HCV) antibodies using an HBV enzyme-linked immunosorbent assay (ELISA) and an HCV ELISA, respectively (Siemens Healthcare Diagnosis). Qualitative PCR amplification was used for plasma HCV amplification (COBAS Amplicor, Roche Diagnosis); the test had a detection limit of 15 IU/mL. + ) were analyzed in the CD4 T cell subset. Anti-CD45RA-FITC, anti-CD31-PE, and anti-CD45RO-PCy7 were obtained from BD Biosciences, and anti-CD4-ECD, anti-CD8-ECD, and anti-CD27-PCy5 were obtained from Beckman Coulter. Cellular activation of CD4 and CD8 T cell subsets was determined by staining PBMCs with anti-HLADR-ECD (Beckman Coulter) and anti-CD4-FITC, anti-CD38-PE and anti-CD8-PerCP (BD Biosciences).
T reg cells were characterized by using the CD4 + CD25 +/ hi FoxP3 + phenotype, as we have described elsewhere [21] . Although FoxP3 is the most unambiguous marker of T reg cells [19] , recent studies indicate that T reg cells down-regulate the expression of the IL-7 receptor (CD127), and a high correlation was found between levels of CD4 + CD25 +/hi
FoxP3
+ and CD4 + CD25 +/hi CD127 lo in healthy subjects [20] . However, we have recently found that CD4 + CD25 hi CD127 lo does not accurately identify T reg cells in all populations of HIV-infected persons, because it depends on the viral load [21] . Thus, because the present study included HIV-infected subjects independent of their viral load, T reg cell frequency was determined by the CD4 + CD25 +/hi FoxP3 + phenotype, using anti-FoxP3-PE (eBioscience) and anti-IL2R1 (CD25)-FITC and anti-CD4-ECD (Beckman Coulter). Additionally, we tested the coexpression of CTLA-4 and GITR in T reg cells, as possible markers of the activation and/or functional status of T reg cells, using anti-CTLA4-PECy5 (BD Biosciencies), anti-GITR-biotine (R&D Systems), and Streptavidine-PECy7 (Beckman Coulter). The intracellular FoxP3 and CTLA4 staining was performed using 
RESULTS
Characteristics of HIV-infected subjects.
Forty HIV-infected subjects, 38 of them white (95%) and 2 of them black (5%), were included in the study, and 39 of them fully completed the immunization protocol. Demographic, clinical, and immunological characteristics of the subjects are summarized in Table 1 . One subject had an insufficient blood sample to evaluate the antibody titer after the second dose of vaccine, although his final response could be evaluated, and a different subject was not available for his final response analysis, although he had received all doses of vaccine. Thus, we obtained results of HBV vaccine response from 40 subjects for very early response, 39 subjects for early response, and 39 subjects for final response.
Rate of seroconversion. Although our objective in this study was not to evaluate the effectiveness of the optimized protocol used for immunization against HBV, we analyzed the humoral immune response (anti-HBs titers) after each dose of vaccine was administered. Thus, only 5 (12.5%) of 40 subjects were very early responders, whereas 15 (38.5%) of 39 subjects were early responders and 29 (74.4%) of 39 subjects were final responders to HBV vaccine.
Associated factors to the HBV vaccine response. Characteristics of final nonresponders ( ) and responders n p 10 ( ) to HBV vaccine are summarized in Table 2 . There n p 29 were no differences between the two groups with respect to sex, age, CD4 T cell counts, weight, smoking or injection drug use status, time of diagnosis, or HIV load levels. Furthermore, no differences were found in cellular parameters, such as frequencies of naive or memory CD4 or CD8 T cells, their activation levels, or the RTE percentage. Only the baseline T reg cell frequency and the percentage of this subset that coexpressed CTLA-4 and GITR were found to be significantly different between both groups ( Figure 1A and 1B, respectively).
We also evaluated the factors associated with the HBV vaccine response of early nonresponders ( ) and early ren p 24 sponders ( ). As well as in the final response, only basen p 15 line T reg cell frequency was significantly higher in the early nonresponders than in the early responders (median [ ). No other differences were P p .040 found between early nonresponders and early responders in the other studied parameters, either demographic or immunological (data not shown). The very early response was not analyzed because of the low number of very early responders.
We then performed a multivariate analysis in which, in addition to T reg cell variables, the following variables traditionally associated with the nonresponse to HBV vaccine were included in both early and final response models: age, sex, HIV load, CD4 T cell count, and antiretroviral therapy. As can be seen in Table 3 , logistic analysis revealed that the baseline T reg cell frequency was the unique variable independently associated with the final nonresponse to HBV vaccine (odds ratio [OR], 0.169; 95% confidence interval [CI], 0.051-0.561; ), P p .004 whereas the coexpression of CTLA-4 and GITR in this subset was the unique variable independently associated with the early response to HBV vaccine (OR, 1.129; 95% CI, 1.016-1.225;
). P p .025 
Relationship between anti-HBs titers and baseline T reg cell frequency.
To deeply analyze the relationship between humoral response to HBV vaccine and T reg cell frequency, subjects were distributed into groups on the basis of their final antiHBs titers, as described elsewhere [22] . Thus, one group included subjects with an anti-HBs level of !10 mIU/mL (nonresponders), a second group included subjects with an anti-HBs level of 10-99 mIU/mL (poor responders), and the last group included subjects with an anti-HBs level of у100 mIU/mL (good responders). As shown in Figure 2A , baseline T reg cell frequency showed a negative association with the antibody titer, because good responders had the lowest T reg cell frequency compared with poor responders ( ) and nonresponders P p .08 ( ). Using the coexpression of CTLA-4 and GITR in P p .001 this subset instead of its frequency, we found an inverse association (data not shown), with the nonresponders having the lowest value, compared with poor responders ( ) and P p .011 good responders ( ). Interestingly, no association was P p .015 found between anti-HBs titers and HIV load or CD4 count ( Figure 2B ).
DISCUSSION
In this study, baseline T reg cell frequency was independently associated with the nonresponse to HBV vaccine in HIV-infected subjects. Furthermore, a negative association between baseline frequency of T reg cells and antibody titers was found in the final response model. These findings suggest an active role played by T reg cells on the immunization antigen-specific T and/or B cell responses with the final consequence of a B cell anti-HBs lower production.
Several mechanisms mainly related to functional defects in both T and B cells have been proposed to explain the nonresponse to HBV vaccine [5, [23] [24] [25] [26] [27] . In fact, previous evidence exists about the inability of T cells to be activated after stimulation with HBs antigen in nonresponders to HBV vaccine [6] , and about the strengthened CD4 and CD8 T cell responses generated when there is a depletion of T reg cells before immunization or infection in animal models [12] [13] [14] . These results, together with the higher frequency of T reg cells reported among HIV-infected subjects, compared with healthy subjects [17] , directed us to hypothesize that an increased frequency of baseline T reg cells could be involved in the poor response to HBV vaccine described in HIV-infected subjects.
In accordance with our results, a recent work [28] showed higher T reg cell levels in healthy nonresponders than in responders to a standard protocol of HBV vaccination, 15 days after receipt of the third dose of vaccine. Because previous researchers did not check baseline T reg cell frequency, they could not establish whether T reg cell implication was dependent on their baseline levels or on an antigen-driven expansion of the number of T reg cells during the vaccination protocol. Recently, an antigen-driven expansion in response to HBV antigen has been suggested to occur in revaccinated liver transplant recipients [29] . Additional investigation needs to clarify whether an abnormally high baseline T reg cell frequency in nonresponders is maintained during the HBsAg immunization or whether it could be even increased by antigen-driven expansion, since this expansion is the real determinant in the final response.
We have tried to analyze for the first time the coexpression of CTLA-4 and GITR in the T reg cell subset as a possible marker of the activation and functional status of T reg cells, because these 2 markers have been related to the cell-to-cell contact mediating suppressive function of T reg cells [30] . As far as we know, no previous experience exists trying to analyze the activation and functional status of T reg cells on the basis of this or another immunophenotyping method, although it could be a good tool in avoiding functional analyses. What we expected to find was a highly functional status of T reg cells associated with a higher T reg cell frequency. However, the paradoxical discrepancy between frequency of T reg cells and the coexpression of CTLA-4 and GITR in this subset that was found in our study, together with the discrepancies from other studies, suggests that this immunophenotyping is not directly related to the functional capability of T reg cells. In this sense, the specific mechanisms of action of T reg cells are not completely understood. Thus, CTLA-4 expression could be only necessary in particular immune responses, as a result of the fact that it could be supplied for other molecules in the T reg cell development and suppressive function [31] . These and our results suggest that the potential role played by these markers requires further investigation.
In our study, we observed that a high T reg cell frequency prior to vaccination was the best predictive marker for the absence of a final effective humoral response. However, attending to the early response to the HBV vaccine (after administration of the second dose), the lower coexpression of CTLA-4 and GITR in the T reg cell subset was the best predictor of nonresponse. We could only speculate about these results, but functional assays are needed to verify the involvement of the modulation of functional capabilities in T reg cells during the HBV vaccination in these subjects.
In addition to T reg cell frequency, other cellular parameters, such as distribution of T cell subsets or their degree of activation, were analyzed. Nonresponders showed lower levels of RTEs, although the difference in comparison to responders was not statistically significant. In contrast, a higher percentage of memory CD4 T cells, but only a trend to higher proportions of naive CD4 T cells, was previously reported in a group of responders to HBV vaccine, although none of these parameters were retained in the multivariate model [5] . The same was noted when activation levels were analyzed, in which only higher levels of activation, measured as CD4 + CD38 + HLA-DR + cell levels, were found in nonresponders, although the difference in comparison to responders was not statistically significant. It is important to note that T cell activation may predict CD4 T cell depletion during HIV infection better than HIV load does [32] .
Our study shows a statistically significant inverse correlation between the baseline T reg cell frequency and antibody titers achieved after complete the booster of vaccination. Interestingly, antibody titers were dependent neither on HIV load levels nor on CD4 counts. Although HIV load levels are usually considered a good indicator of response to vaccine [33, 34] , the absence of association in our study could be explained, at least partially, on the basis of both the small sample size analyzed and the relatively low viral load of vaccinated subjects. In fact, only 7 of 40 subjects had HIV loads of 120,000 copies/mL, and only 3 of them had HIV loads 150,000 copies/mL. It is important to note that vaccination is not normally advised in HIV-infected subjects with CD4 T cell counts of !350 cells/mL or HIV loads of 150,000 copies/mL [4] . It is important to note that viremia could be an underlying effect for the increase in T reg cell frequency. In this sense, an expansion of T reg cells has been reported in HIV-infected subjects directed to contain the immune hyperactivation associated with high viral loads [35] . Furthermore, FoxP3 could repress retroviral transcription, making T reg cells more resistant to HIV infection than are other T effector cells [36] . On the other hand, in a recent study it had been reported that nonresponse in HIV-infected subjects was associated only with the level of CD4 and age [37] and not with HIV load. Regarding CD4 counts, all of our subjects had counts of 1350 cells/mL, which was an inclusion criterion, and such good immune status could explain the absence of association between response and CD4 T cell counts in our study. On the other hand, although advanced age has been shown to decrease the immunogenicity of HBV vaccine in healthy [38] and in HIV-infected subjects [37] , most of our subjects were !40 years old, which could also explain the absence of this association in our group of subjects.
One limitation of our study is the global small sample size and the small number of nonresponders (only 10) to the HBV vaccine, which limits the power of the multivariate analysis. Moreover, our results could not necessarily be extrapolated to other immunosuppressive scenarios or different HIV clinical status as a result of the relatively good health of our cohort. However, our results contribute to the knowledge of T reg cell behavior during vaccination against HBV in HIV-infected subjects, which could be useful for design innovative therapies complementary to the vaccination protocols to improve the seroconversion rate in these subjects. In this sense, anti-CD25 antibody (Daclizumab) has been reported to be an available therapeutic agent for targeting T reg cells [39, 40] . On the other hand, additional studies, including more determinations of T reg cell frequency during the vaccination protocol and functional assays, would allow interesting kinetic analysis of the potential antigendriven expansion of T reg cells during HBV immunization.
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